Oxaliplatin, which is used in various chemotherapy regimens, including FOLFIRINOX, for the treatment of pancreatic cancer, has also been shown to have an inhibitory effect on CYP2C9 (21). Here, CYP2C9 is linked to familial pancreatic carcinoma.